Alison Betts Email and Phone Number

Sr. Director of Scientific Collaborations, Fellow of Modeling & Simulation

• Translation modeling and simulation team leader, supervising a team of modelers providing translational quantitative systems pharmacology (QSP) modeling and strategic direction to all large molecule oncology programs in the Pfizer portfolio.• Provide guidance in the selection of compounds and viability of targets from idea to proof of concept.• Use Modeling and Simulation tools to provide quantitative multi-scale predictions of pharmacokinetics, biomarker endpoints and clinical efficacious dose.• Recognized global leader/expert in PK/PD modeling of large molecules at Pfizer; established large molecule PK prediction guidance and platform PK/PD and PBPK models for a range of biotherapeutic modalities including mAbs, antibody-drug conjugates, diabodies, scfvs, proteins and peptides; facilitating quantitative decision making across a wide range of RUs.• Recognized expert in quantitative modeling of Antibody Drug Conjugates. Provide scientific direction and guidance on ADCs externally as a frequent invited speaker at scientific meetings and symposia.• Specialize in QSP modeling of immune-oncology drugs including T-cell retargeting modalities and checkpoint inhibitors.

• Oncology Research Unit Modeling and Simulation lead, within department of Pharmacokinetics, Dynamics and Metabolism.• PK/PD team leader providing PK/PD modeling and translational pharmacology strategic direction to the Biologics section of the Oncology Research Unit. • Provide guidance in the selection of compounds and viability of targets from idea to proof of concept.• Use Modeling and Simulation tools to provide quantitative multi-scale predictions of pharmacokinetics, biomarker endpoints and efficacious dose.• Leader of the Pfizer Biotherapeutics Modeling and Simulation Working Group which has successfully implemented platform PK/PD and PBPK models for a range of biotherapeutic modalities including mAbs, CovX bodies, antibody-drug conjugates, oligonucleotides and nanobodies, facilitating quantitative decision making across a wide range of RUs.• Recognized expert in quantitative modeling of Antibody Drug Conjugates.

• PK/PD team leader responsible for the successful execution of PK/PD modeling and translational strategy across the Antibacterials portfolio including projects from exploratory stage through to Phase 1 clinical development.• Identified business need and implemented new translational pharmacology strategies including increased use of in vitro tools and time course modeling of in vitro and in vivo antibacterial data.• Established in vitro: in vivo correlations so that in vitro models could be used to predict in vivo outcomes. This work resulted in a reduction in in vivo animal spend by 40%. Awarded Pfizer Animal Care and Welfare Board ‘Reduce, Re-use and Refine’ award 2010.• Implemented mechanism based PK/PD, PBPK and systems pharmacology models to predict efficacy and emergence of resistance and used these to develop novel strategies for clinical dose predictions of antibacterial drugs.• Leader of the cross-line Translational Pharmacology Team which was awarded a Pfizer Leadership Team Excellence Award 2009.• Established multiple external partnerships with leading anti-infective PK/PD groups, including University of Buffalo and ABRU Translational Medicine alliance, Ordway Research Institute of Infectious Diseases and ICPD) resulting in the advancement of PK/PD modeling in infectious diseases and its application to augment antibacterial drug discovery.